NCRI 2018 | Current treatment landscape of triple negative breast cancer
Adrian Harris
• 4 Nov 2018
In this video, Adrian Harris, MD, DPhil, from the University of Oxford, Oxford, UK, compares the roles of platinum-based drugs and taxanes in triple negative breast cancer (TNBC), before discussing the intriguing progression-free survival and overall survival results from a recent study that compared PD-L1 blocking drugs with taxanes. The results are from an early trial and Prof. Harris hopes they will lead to further studies to potentially identify the expression of PD-L1 as a classifier for targeted therapy. This video was recorded at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK.
